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Transarterial radioembolization (TARE)with 90Ymicrospheres delivers low dose rate radiation (LDR) to intrahepatic tumors.
In the current study,we examined clonogenic survival, DNAdamage, and cell cycle distribution in hepatocellular carcinoma
(HCC) cell lines treatedwith LDR in combinationwith varyingdoses and schedules of 5-fluorouracil (5-FU), gemcitabine, and
sorafenib. Radiosensitization was seen with 1 to 3 μM 5-FU (enhancement ratio 2.2–13.9) and 30 to 100 nM gemcitabine
(enhancement ratio 1.9–2.9) administered 24 hours before LDR (0.26 Gy/h to 4.2 Gy). Sorafenib radiosensitized only at high
concentrations (3–10 μM) when administered after LDR. For a given radiation dose, greater enhancement was seen with
LDR compared to standard dose rate therapy. Summarizing our clinical experience with low dose rate radiosensitization,
13 patients (5 with HCC, 8 with liver metastases) were treated a total of 16 times with TARE and concurrent gemcitabine.
Six partial responses and one complete response were observed with a median time to local failure of 7.1 months for all
patients and 9.9 months for patients with HCC. In summary, HCC is sensitized to LDR with clinically achievable
concentrationsof gemcitabineand5-FU in vitro.Encouraging responseswereseen in a small cohort of patients treatedwith
TARE and concurrent gemcitabine. Future studies are needed to validate the safety and efficacy of this approach.
Translational Oncology (2014) 7, 472–478Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
deaths worldwide [1]. Transarterial radioembolization (TARE) with
yttrium-90 (90Y) microspheres is one of the many treatment options
available for patients with unresectable HCC. Because tumors in
the liver derive most of their blood supply from the hepatic artery
versus the portal vein [2], this therapy preferentially targets the tumor
and spares uninvolved liver parenchyma. Prior reports have shownthat TARE with 90Y microspheres is associated with a 42% partial
response rate [3,4] and longer progression-free survival than
chemoembolization [5].
Concurrent chemoradiotherapy has proven to be more efficacious
than radiation alone in the majority of gastrointestinal malignancies.
A drug which preferentially sensitizes HCC to the cytotoxic effects of
low dose rate radiation (LDR) produced by 90Y microspheres would
potentially improve the efficacy of this therapy. Candidate drugs
for radiosensitization include gemcitabine and 5-fluorouracil (5-FU)
in addition to agents with known efficacy in HCC such as sorafenib.
Gemcitabine and 5-FU are used routinely in combination with external
beam radiation therapy for several intra-abdominal malignancies
including pancreatic and gastric cancer [6–8]. Sorafenib was shown in
a preclinical study to be an effective radiosensitizer in HCC when given
after radiation therapy but not when given before treatment [9].
In the current study, we evaluated the potential of gemcitabine, 5-FU,
and sorafenib to radiosensitize HCC to 90Y microspheres. Because the
mean dose rate achieved during an administration of 90Ymicrospheres is
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could deliver a dose rate in this range. We assessed clonogenic survival,
DNA damage repair, and cell cycle distribution in HCC cells in vitro.
Additionally, we report our early clinical experience of combining
TARE with gemcitabine in patients with primary liver cancer and
liver metastases.
Materials and Methods
Cell Culture and Drug Treatment
Human HCC cell lines (Hep3B, HepG2) were maintained in F-12
or RPMI media supplemented with 10% fetal bovine serum and
penicillin/streptomycin. Experiments involving 5-FU were carried
out in dialyzed serum with leucovorin. Gemcitabine (Eli Lilly,
Indianapolis, IN), 5-FU/leucovorin (Sigma-Aldrich, St. Louis, MO),
and sorafenib (University of Michigan Pharmacy, Ann Arbor, MI)
were tested in combination with LDR. Drugs were diluted in PBS
to appropriate concentrations which were selected to correspond to
clinically achievable levels.
Radiation Techniques
LDR was delivered using a custom-built LDR device consisting of
an array of cesium-137 sources. This array is shielded by interlocking
6-cm–thick pieces of Cerrobend and resides inside a cell culture
incubator at 37°C. Dose homogeneity determined by film was within
±5%. Cells were irradiated at a dose rate of 0.07, 0.10, or 0.26 Gy/h
for 16 hours to a total dose of 1.1, 1.6, or 4.2 Gy. Standard dose rate
radiation (SDR) was delivered using a Philips RT250 orthovoltage
unit (Kimtron Medical, Oxford, CT) at a dose rate of approximately
2 Gy per minute to a total dose of 2 to 4 Gy. Dosimetry was
carried out using an ionization chamber connected to an electrometer
system directly traceable to a National Institute of Standards and
Technology calibration.
Clonogenic Survival Assay
After radiation was complete, cells were suspended and counted
then plated at set densities based on the dose of radiation received.
Cells were incubated until visible colonies were present. Colonies
were fixed with methanol/acetic acid (7:1) and stained with crystal
violet. The number of colonies containing ≥50 cells was determined.
Enhancement ratios were calculated by dividing the surviving fraction
without drug by the surviving fraction with drug for each dose
of radiation with an adjustment for plating efficiency. Experiments
were performed in at least triplicate, and the mean and standard error
were calculated.
Cell Cycle Distribution
Cell cycle distribution was determined using propidium iodide (PI,
0.018 mg/ml) staining and flow cytometry. Cells were fixed in 70%
ethanol at the appropriate time points then incubated with PI before
quantification using flow cytometry. Trout erythrocytes were
used as the internal standard. Data were analyzed using FlowJo
(Tree Star, Ashland, OR). Single-cell populations were gated, and
histograms were modeled using the Watson method. A fixed distance
between the G1 and G2 peaks was used for each cell line based on
untreated controls.
γH2AX Detection
Cells were fixed with 70% ethanol after treatment at the appropriate
time points. Fixed cells were incubated with anti-γH2AX mouseantibody (Millipore, Billerica, MA) at a concentration of 1:500
overnight followed by fluorescein isothiocyanate–labeled anti-mouse
secondary antibody (Sigma-Aldrich) for 2 hours. Cells were then
counted with flow cytometry. Trout erythrocytes were used as the
internal standard. FlowJo software was used to quantify the percentage
of cells staining positive for γH2AX.
Transarterial Radioembolization and Gemcitabine
in Patients
Thirteen patients with primary liver cancer or liver metastases were
treated with a single dose of gemcitabine (200–400 mg/m2) 1 day
before TARE with TheraSpheres (Nordion, Ottawa, Canada).
Radioembolization dose was defined as the dose to the entire lobar
volume. Response was determined based on the Response Evaluation
Criteria in Solid Tumors (RECIST). Survival endpoints were
calculated from the start of treatment. Local failure was defined as
progression in the region of the liver targeted with TARE. Patient were
typically seen 1, 3, and 6 months after treatment with follow-up
imaging obtained 2 to 3 months after treatment then every 4 to 6
months or as clinically indicated. Data were retrospectively collected
and analyzed under an Institutional Review Board–approved protocol.
Statistical Analysis
The mean and standard error were calculated using Microsoft Excel
Software (Seattle, WA). For in vitro studies, a Student’s t test was
used to compare treatment groups. A P value of ≤ .05 was considered
statistically significant. Experiments were performed in at least
triplicate to ensure reproducibility. The Kaplan-Meier method was
used to determine overall survival, local progression-free survival, and
time to local failure for all patients treated. Median survival was
calculated with JMP software (version 10; SAS, Cary, NC).
Results
Low Dose Rate Radiosensitization
To test our hypothesis that systemic therapy enhances the cytotoxic
effect of LDR, we first determined the optimal schedule and
concentration of each agent. Clonogenic survival assays with HCC cell
lines were performed using gemcitabine, 5-FU/leucovorin, and sorafenib
at different dosing schedules. Schedules were chosen based on our
experience using these agents with external beam radiation therapy. For
gemcitabine, cells were treated for 2 hours either 1 day before or just
before LDR. Both schedules resulted in effective radiosensitization at a
cytotoxic concentration of gemcitabine (100 nM); however, at
noncytotoxic concentrations (10–30 nM), treatment 24 hours before
LDR was required for optimal radiosensitization (Figure 1A). Similar to
our findings with gemcitabine, treatment with 5-FU resulted in greater
radiosensitization if started 24 hours before LDR compared to treatment
just before LDR (Figure 1B). This schedule provided greater
enhancement ratios at cytotoxic (3–10 μM) and noncytotoxic
concentrations (1 μM) of 5-FU.
Prior reports demonstrate that sorafenib radiosensitizes if adminis-
tered after radiation but has protective effects if given before [9]. Using
this information, we treated cells with sorafenib at the start of or
immediately after LDR. Sorafenib was not an effective radiosensitizer at
noncytotoxic concentrations (0.3–1 μM) with either dosing schedule.
However, at a cytotoxic concentration (10 μM), radiosensitization was
observed with both schedules (Figure 1C).
Using the optimal dosing schedules determined from the prior
experiment, we next tested the effect of changing the radiation dose
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Figure 1. Effects of dose and schedule of systemic therapy on LDR radiosensitization. HepG2 cells were treated with gemcitabine (A), 5-FU
(B), or sorafenib (C) at the indicated doses and schedules in combination with LDR (0.26 Gy/h to 4.2 Gy). Cells were assayed for clonogenic
survival 24 hours after LDR. Shown are the mean enhancement ratios with standard error (n ≥ 3 for each condition).
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dose rate over the LDR range (from 0.07 to 0.10 to 0.26 Gy/h)
resulted in increasing levels of radiosensitization with gemcitabine and
5-FU in both HCC cell lines (Table 1). Radiation delivered at a
standard dose rate (2 Gy/min or 120 Gy/h) was associated with less
radiosensitization compared to LDR for gemcitabine and 5-FU atTable 1. Radiosensitization in Hepatocellular Carcinoma
Dose rate
Total dose
Gem
30 nM
Gem
100 nM
5-FU
1 μM
5-FU
3 μM
Sorafenib
3 μM
Sorafenib
10 μM
A. Enhancement Ratios for Hep3B Cells with Low and Standard Dose Rate Radiation
LDR 0.07 Gy/h
1.1 Gy
0.99 1.14 2.26 1.81 1.61 1.19
LDR 0.10 Gy/h
1.6 Gy
1.62 1.55 1.02 3.51 1.22 2.36
LDR 0.26 Gy/h
4.2 Gy
1.90 2.31 7.92 13.85 1.58 5.55
SDR 2 Gy/min
2 Gy
1.27 1.73 1.48 1.18 1.14 1.58
SDR 2 Gy/min
4 Gy
1.03 1.41 1.87 2.84 1.56 2.09
B. Enhancement Ratios for HepG2 Cells with Low and Standard Dose Rate Radiation
LDR 0.07 Gy/h
1.1 Gy
2.06 2.69 1.89 2.09 0.91 4.19
LDR 0.10 Gy/h
1.6 Gy
2.42 2.83 2.03 1.95 1.24 4.50
LDR 0.26 Gy/h
4.2 Gy
2.16 2.87 2.16 3.30 1.05 2.61
SDR 2 Gy/min
2 Gy
1.63 0.94 0.92 1.72 1.10 1.48
SDR 2 Gy/min
4 Gy
1.53 1.19 2.45 1.79 1.46 1.11most concentrations tested (Table 1). Overall, these data suggest that
combining gemcitabine or 5-FU with LDR produced by 90Y
microspheres is potentially an efficacious strategy in HCC.
Effect of Gemcitabine and 5-FU on LDR-Induced
DNA Damage
Given the promising findings from the clonogenic survival assays,
we next studied the formation and resolution of DNA double-strand
breaks using γH2AX immunostaining and flow cytometry. Cells were
treated with LDR (0.26 Gy/h for 16 hours) and gemcitabine or 5-FU%
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Figure 2. Formation and resolution of γH2AX foci. HepG2 cells
were treated with 30 nM gemcitabine for 2 hours 1 day before LDR
(0.26 Gy/h to 4.2 Gy). Cells were fixed and incubated with
anti-γH2AX antibody and then analyzed by flow cytometry.
Shown are the mean percent cells with DNA double-strand breaks
after completion of LDR (n = 4).
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gemcitabine and LDR resulted in more unresolved DNA double-
strand breaks in the HepG2 cell line immediately after radiation was
complete (16 hours from the start of LDR). Flow cytometry analysis
showed that 35% of HepG2 cells treated with gemcitabine and LDR
were positive for γH2AX compared to 12% of cells treated with
gemcitabine alone (P = .03) and 17% of cells treated with radiation
alone (P = .07). These differences persisted at 6 and 24 hours after
LDR (Figure 2).
For comparison, the above experiment with γH2AX was repeated
using standard dose rate radiation (2 Gy/min) in place of LDR. We
anticipated that there would be less DNA damage and/or impaired
DNA repair in cells treated with SDR compared to LDR due to the
lower levels of radiosensitization seen in the clonogenic survival study.
Shortly after radiation (0–6 hours), HepG2 cells treated with radiation
at either dose rate had a similar amount of DNA double-strand breaks
with and without 30 nM gemcitabine. However, 24 hours after
radiation, gemcitabine-treated HepG2 cells receiving LDR had
impaired resolution of γH2AX (19% cells positive) compared to SDR
(4% cells positive). These results suggest that DNA repair is impaired
more in gemcitabine -treated cells receiving LDR compared to SDR.
The effect of 5-FU on the formation and resolution of LDR-
induced DNA double-strand breaks was tested in a similar fashion as
gemcitabine. Treatment with 5-FU and LDR was associated with
more γH2AX-positive cells in the HepG2 cell line compared to 5-FU
or LDR radiation alone. Treatment of HepG2 cells with 1 μM 5-FU
and LDR resulted in 48% γH2AX-positive cells immediately after
radiation was complete compared to 13% with 5-FU alone or RT
alone, suggesting that 5-FU and LDR interact to induce DNA
damage and/or impair DNA damage repair.
Effects of Gemcitabine or 5-FU and LDR Radiation on Cell
Cycle Distribution
To further understand the mechanism behind LDR radiosensitiza-
tion with gemcitabine and 5-FU, we next studied the effects of
these treatments on cell cycle distribution. Treatment with 30 nM
gemcitabine with LDR (0.26 Gy/h to 4.2 Gy) had significant cell
cycle effects in the Hep3B cell line. Immediately after 16 hours of
LDR, Hep3B cells treated with gemcitabine were more likely to be in
G2/M phase (24%) than cells treated with RT alone (7%, P = .009)
or gemcitabine alone (14%, P = .015) (Figure 3). This difference
persisted at 2, 6, 12, and 24 hours after radiation (Figure 3C).
Additionally, treatment with gemcitabine alone led to an increase in
the number of Hep3B cells in S phase 24 hours later (corresponding
to the start of LDR). In the HepG2 cell line, treatment with
gemcitabine plus LDR resulted in a similar number of cells in G2/M
as treatment with LDR alone, whereas treatment with gemcitabine
alone was associated with a higher percentage of cells in S phase.
Similar to gemcitabine, we tested the effects of 5-FU and sorafenib
on cell cycle in combination with LDR. Treatment with 3 μM 5-FU
resulted in an increased number of cells in S phase compared
to controls in both HepG2 (37% vs 57%, P b .001) and
Hep3B (36% vs 54%, P = .06) cell lines (Figure 3). Additionally,
adding 5-FU to radiation resulted in a higher percentage of cells in
S phase in HepG2 (31% vs 54%, P = .01) and Hep3B (24% vs 59%,
P = .01) cell lines compared to cells treated with LDR alone
(Figure 3B). These data suggest that 5-FU induces S phase arrest in
cells undergoing LDR. Of note, treatment with sorafenib after LDR
did not significantly alter cell cycle distribution.Clinical Experience with Liver Radioembolization and
Concurrent Gemcitabine
Based on our preclinical results showing gemcitabine is an effective
LDR radiosensitizer, we performed a review of our clinical experience
with gemcitabine in combination with radioembolization. Thirteen
patients with primary liver cancer or liver metastases were treated
with 90Y microspheres and concurrent gemcitabine administered 24
hours before TARE. Three patients were treated to separate lobes of
the liver at different times. Table 2 shows the characteristics of each
patient with the doses of radiation and gemcitabine they received.
Five patients were treated for liver-confined unresectable HCC,
seven patients for metastatic melanoma, four patients for metastatic
cholangioncarcinoma, and one patient for metastatic carcinoid. Three
of the five patients withHCC had cirrhosis (all Child-Pugh score A), and
three of the patients were HCV positive. A noncytotoxic gemcitabine
dose of 200mg/m2 (standard therapeutic dose is 1000mg/m2) was used
for 14 of the 16 treatments.
We reviewed the records of the 13 patients to determine treatment-
related toxicity. The mean total bilirubin for the entire group did
not change from baseline (0.68 mg/dl) to 1 month (0.68 mg/dl).
However, at 3 and 6 months after TARE, the mean bilirubin of the
group was higher at 0.95 mg/dl and 1.05 mg/dl, respectively.
A clinically significant increase defined as a rise above 1.2 mg/dl was
only seen in two patients at 3 and 6 months. In these patients, the rise
in bilirubin was associated with an increased burden of disease.
Absolute neutrophil or lymphocyte count did not substantially
change from baseline to 1 month or 3 months after treatment.
No patient developed neutropenia defined as a neutrophil count
of less than 1500 per microliter. Clinically, two patients developed
worsening ascites following treatment requiring hospitalization and/or
intervention. It is unclear if their ascites were directly related to treatment
or tumor progression. No variceal bleeding or encephalopathy was seen
following treatment. One patient developed a duodenal ulcer months
after TARE which was attributed to antiangiogenic therapy.
For all patients, median survival from the time of gemcitabine plus
TARE was 12.3 months, and the time to local failure, defined as
progression in the region targeted by TARE, was 7.1 months. In the
five patients with liver-confined HCC there were one complete
response, three partial responses, one patient with stable disease, and
one patient with no response/progressive disease after treatment
(Figure 4). Median time to local failure was 9.9 months and overall
survival was 12.5 months for the patients with HCC. The eight
patients treated for liver metastases had a median survival of 9.2
months and time to local failure of 6.4 months (Table 2). Overall,
these findings suggest that radiosensitizing doses of gemcitabine
can be combined with 90Y microspheres in patients with HCC and
liver metastases.
Discussion
Despite the proven benefit of adding chemotherapy to radiation in
most GI malignancies, combining chemotherapy with 90Y micro-
spheres for HCC has not been previously studied. In the current
study, we found that gemcitabine and 5-FU were effective
radiosensitizing agents at noncytotoxic and clinically achievable
concentrations in HCC cell lines treated with LDR (0.07–0.26 Gy/h).
Interestingly, the level of radiosensitization with LDR was greater than
what was observed in cells treated with SDR (2 Gy/min) under
otherwise similar conditions. Sorafenib produced radiosensitization
when administered after LDR; however, the doses required to
LDR alone
4.2 Gy
Control Gemcitabine
5-FU
Gemcitabine + LDR
5-FU + LDR
G1
G2/M
S
Pe
rc
en
t c
el
ls
 in
 G
2/
M
Hours after Radiation
0
10
20
30
40
50
60
70
80
90
100
%G1 %S %G2
0
10
20
30
40
50
60
70
80
90
100
%G1 %S %G2
HepG2 Hep3B
A
B
C
Figure 3. Effect of gemcitabine and 5-FU on LDR-induced cell cycle changes. HCC cell lines were treated with 30 nM gemcitabine or 3 μM
5-FU 24 hours before LDR (0.26 Gy/h for 16 hours). Cells were stained with PI and analyzed by flow cytometry. Shown are representative
histograms at 24 hours after LDR (A), cell cycle distribution after LDR (B), and the percentage of Hep3B cells in G2/M at the indicated time
points after LDR (C).
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Table 2. Patients Treated with 90Y Microspheres and Gemcitabine
Radiation Dose Gy ¶ Gemcitabine Dose mg/m2 Diagnosis Number of Lesions Vascular Involvement Overall Survival Months Time to Local Failure Best Response (RECIST)
1 99.3 200 Hepatocellular 8 No 6.9 6.9 ‡ CR
2A § 80.2 200 Hepatocellular 4 No 32.9 * 16.8 PR
2B§ 155.0 200 Hepatocellular 4 No 17.9 PR
3 85.3 200 Hepatocellular 2 Yes 12.3 9.9 PR
4 115.7 400 Hepatocellular 1 No 21.1 * 3.8 PD
5 130.0 200 Hepatocellular 5 No 12.5 7.1 SD
6A § 97.4 200 Melanoma 8 No 27.7 6.4 PR
6B§ 134.5 200 Melanoma N10 No 7.8 PR
7 102.4 200 Melanoma N10 No 5.0 1.6 PR
8 89.0 200 Melanoma N10 No 6.6 † 3.4 PD
9A § 103.7 200 Melanoma N10 No 9.2 6.8 SD
9B§ 109.8 200 Melanoma N10 No 4.9 PD
10 85.7 200 Melanoma N10 No 15.9 9.3 SD
11 124.4 200 Cholangio N10 No 2.2 2.2 ‡ PD
12 110.2 400 Cholangio N10 Yes 5.5 6.4 PD
13 92.7 200 Carcinoid N10 No 10.4 10.4 ‡ SD
* Alive at time of analysis.
† Lost to follow up.
‡ No local progression at time of death.
§ Treated to separate regions at different times.
¶ Calculated dose to lobe.
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patients. Given these results, gemcitabine and 5-FU are promising agents
to combine with 90Y microspheres, whereas sorafenib may not produce
more than an additive effect at clinically relevant concentrations.
Gemcitabine and 5-FU are antimetabolites with different
mechanisms of action. Gemcitabine radiosensitizes by depleting
phosphorylated deoxynucleotide pools, and maximum sensitization
occurs under conditions producing S phase distribution and dATP
depletion [10–13]. We found that when noncytotoxic concentrations
of gemcitabine were used, an incubation period of 24 hours was
associated with increased radiosensitization compared to treatment
just before LDR. This finding is consistent with prior reports showing
that it takes several hours to deplete dNTP pools [13,14].
Additionally, an increase in the number of cells in S phase was seen
with our dosing schedule consistent with conditions needed for
radiosensitization with gemcitabine [13,14]. 5-FU’s main mechanism-1.0
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Figure 4. Response rate of patients treated with TARE and
concurrent gemcitabine. Five patients with liver-confined HCC
underwent treatment with 200 to 400 mg/m2 gemcitabine 1 day
before TARE. One patient was treated to separate lobes of the liver
at different times. Shown is the percent change in size of the target
lesion based on RECIST.of action is through inhibition of thymidylate synthase [15]. In our
study, 5-FU was associated with a pronounced S phase arrest in both
HCC cell lines tested. Pretreatment for 24 hours was associated with
improved radiosensitivity at noncytotoxic concentrations. Because
high levels of enhancement were seen at noncytotoxic concentrations,
the mechanism of radiosensitivity is not simply related to killing of
radioresistant cells in S phase. More likely, treatment with 5-FU leads
to inappropriate S phase progression during LDR [16,17].
The findings from our study suggest that LDR and gemcitabine or 5-
FU have complementary effects on cell cycle distribution leading to
enhanced radiosensitivity. LDR alone was associated with G2 arrest
which persisted for ≥24 hours after the 16-hour course of LDR was
complete. LDR-induced G2 arrest is well established and is the basis of
the inverse dose rate effect [18]. Treatment with gemcitabine plus LDR
was associated with a higher percentage of cells in S phase compared to
LDR alone in addition to G2 arrest. Additionally, treatment with 5-FU
produced S phase arrest in both cell lines. Abnormal progression
through S phase in conjunction with LDR-induced G2 arrest would be
predicted to lead to increased radiosensitivity.
The formation and resolution of γH2AX foci provide insight into
the induction of DNA damage and subsequent repair after LDR. As
expected, in our study, we saw increased DNA damage and impaired
DNA double-strand break repair when 5-FU or gemcitabine was
added to LDR. A surprising finding was that DNA double-strand
break repair was impaired for a longer period of time after LDR
compared to cells treated with SDR at the same dose (4 Gy). Prior
reports show that DNA damage is repaired during a course of LDR
[19]. Therefore, one might predict less DNA damage after LDR
compared to SDR therapy at the same dose. In this study, the
percentage of γH2AX-positive cells was relatively similar for each
dose rate when cells were examined shortly after radiation therapy;
however, at 24 hours, treatment with gemcitabine and LDR was
associated with a higher percentage of γH2AX-positive cells
compared to treatment with SDR and gemcitabine. This finding
could be explained by the long time (16 hours) required to deliver
LDR resulting in greater depletion of dNTP pools by gemcitabine.
Alternatively, prolonged exposure to LDR in combination with
gemcitabine (or 5-FU) may cause permanent or prolonged cell cycle
478 Low Dose Rate Radiosensitization of HCC Cuneo et al. Translational Oncology Vol. 7, No. 4, 2014arrest affecting DNA damage response. A prior study found
prolonged exposure to LDR leads to downregulation of critical
DNA repair proteins including DNA-PKcs and Ku70, consistent
with this hypothesis [20].
To our knowledge, this is the first report combining LDR with
radiosensitizing chemotherapy to treat HCC. Treatment with TARE
and concurrent gemcitabine was associated with an encouraging
response in our small patient cohort. Prior reports of TARE have
shown response rates of approximately 40% in HCC using similar
response criteria as used in our study [4,5]. In our experience, four of
six primary liver tumors responded to gemcitabine followed by TARE
including one complete response. Given the small number of patients
and potential for selection bias in our cohort, the safety and efficacy of
this approach cannot be determined.
In conclusion, gemcitabine and 5-FU are effective LDR radio-
sensitizers at clinically achievable concentrations. Given the preclinical
findings, scientific rationale, and local control seen in our experience,
the combination of radioembolization and chemotherapy should be
prospectively studied in a larger patient cohort to determine if this
treatment is safe and more efficacious than TARE alone.
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